Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lazertinib + Chemotherapy in EGFR-mutant NSCLC (CHAMELEON)
NCT06020989Phase 2Not yet recruiting
- Sponsor
- Yonsei University
- Start
- Sep 2023
- Primary completion
- Sep 2024
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of lazertinib in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Yonsei University. Primary endpoint: Progression-free survival up to 100 months. Planned start Sep 2023; status: not yet recruiting.
02
Drugs
lazertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06020989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06020989.